About

About AbilityPharma AbilityPharma is a clinical phase 2b biopharmaceutical company focused on developing first-in-class fully differentiated oral targeted anticancer compounds inducing autophagy-mediated cytotoxicity selectively in cancer cells. A phase 2b trial (140 patients), double-blind placebo-controlled with ABTL0812, in METASTATIC PANCREATIC CANCER, as first-line therapy in combination with FOLFIRINOX, is currently ongoing in Spain, USA, France, and Israel. - All patients already recruited (january 2024) - First blinded efficacy superior results available - Positive interim analysis in April 2024 - Unblinded efficacy results available in 1Q2025 - Series B/C financing round to initiate Phase III development - Out-licensing agreement intended for 2025 The clinical trial is assessing the safety and efficacy profile of ABTL0812 in combination with FOLFIRINOX in 140 patients with advanced pancreatic cancer as first-line treatment. To help funding this trial, we were granted USD 1.9 M in an NIH R01 grant managed by the FDA Orphan Disease Program, and a EUR 5.2 M EIC Accelerator grant from the European Commission H2020 (2.4 grant, 2.8 Equity investment). In 2020 we finished the phase 2a clinical trial in endometrial and squamous lung cancer patients, as first-line therapy in combination with CarboTaxol with very positive results, showing that ABTL0812 combined with chemotherapy is much superior to chemotherapy alone. In the sqNSCLC arm OVERALL SURVIVAL DOUBLED vs historical controls (from 11 to 22 months). ABTL0812 causes irreversible cytotoxic /autophagy selectively in cancer cells through the induction of ER Stress and Akt blockade. Besides its efficacy as single agent, ABTL0812 has synergistic effect with chemotherapy and has synergistic effect with IO therapies (anti-PD1) and acts on the tumor microenvironment turning cold tumors into hot (immunogenic) tumors. AbilityPharma is a clinical phase 2b biopharmaceutical company focused on developing first-in-class fully differentiated oral targeted anticancer compounds inducing autophagy-mediated cytotoxicity selectively in cancer cells. A phase 2b trial (140 patients), double-blind placebo-controlled with ABTL0812, in METASTATIC PANCREATIC CANCER, as first-line therapy in combination with FOLFIRINOX, is currently ongoing in Spain, USA, France, and Israel. - All patients already recruited (january 2024) - First blinded efficacy superior results available - Positive interim analysis in April 2024 - Unblinded efficacy results available in 1Q2025 - Series B/C financing round to initiate Phase III development - Out-licensing agreement intended for 2025 The clinical trial is assessing the safety and efficacy profile of ABTL0812 in combination with FOLFIRINOX in 140 patients with advanced pancreatic cancer as first-line treatment. To help funding this trial, we were granted USD 1.9 M in an NIH R01 grant managed by the FDA Orphan Disease Program, and a EUR 5.2 M EIC Accelerator grant from the European Commission H2020 (2.4 grant, 2.8 Equity investment). In 2020 we finished the phase 2a clinical trial in endometrial and squamous lung cancer patients, as first-line therapy in combination with CarboTaxol with very positive results, showing that ABTL0812 combined with chemotherapy is much superior to chemotherapy alone. In the sqNSCLC arm OVERALL SURVIVAL DOUBLED vs historical controls (from 11 to 22 months). ABTL0812 causes irreversible cytotoxic /autophagy selectively in cancer cells through the induction of ER Stress and Akt blockade. Besides its efficacy as single agent, ABTL0812 has synergistic effect with chemotherapy and has synergistic effect with IO therapies (anti-PD1) and acts on the tumor microenvironment turning cold tumors into hot (immunogenic) tumors.